Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
Objective(s): To investigate the efficacy of pembrolizumab plus lenvatinib as a second-line or later-line therapy in women with advanced or recurrent uterine carcinosarcoma (UCS). Methods: A single-institution pharmacy database was queried for women with advanced or recurrent UCS who were prescribed...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-08-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578921001442 |